{"data":[{"public_id":"RVQUKf41","name":"Selective aging in Acomys cahirinus: linking regenerative biology to healthy aging mechanisms","section":"aging-biology","canonical_url":null,"brief_concise":"This project argues that the Cairo spiny mouse, Acomys cahirinus, may be a useful mammalian model for healthy aging because older animals reportedly retain spatial memory and motor learning better than conventional lab mice while also showing unusual regenerative traits. The strongest support in the evidence is still mixed: the core project record is an internal, prospective description rather than a peer-reviewed outcome, and published field-context studies suggest both resilience signals and important caveats, including delayed and spatially heterogeneous wound regeneration in older animals.","overall_score":43.1,"scientific_overall":51.2,"breakthrough_overall":54.3,"investor_overall":29.02,"last_rated_at":"2026-05-30 01:12:18.278221+00","public_url":"https://eternalsearch.net/ratings/projects/RVQUKf41"},{"public_id":"c5vtNo4T","name":"OpenDrugs","section":"bioinformation","canonical_url":"https://open-drugs.org","brief_concise":"OpenDrugs appears to be an AI-enabled, evidence-first longevity compound database and research workspace built by OpenLongevity for researchers, with search, comparison, visualization, research boards, and candidate-generation workflows across aging-related substances rather than a therapeutic program of its own. The strongest project-specific evidence supports platform scope, architecture, data-source integration, and provenance features, but not outcome validation: the project claims 3.1K indexed substances, 27 synced open sources, 13 animal models, version 2.4 stable dated 2026-05-07, and auditable evidence scoring, while also disclosing that it is a triage/research tool rather than a regulatory or clinical-decision system and showing at least one notable possible data gap via a reported metric of 0 biological targets linked to substances and pathways.","overall_score":52.64,"scientific_overall":55.7,"breakthrough_overall":49.4,"investor_overall":51.98,"last_rated_at":"2026-05-29 14:51:34.387316+00","public_url":"https://eternalsearch.net/ratings/projects/c5vtNo4T"},{"public_id":"7YOQoxeA","name":"Frontier Bio","section":"bioreplacement","canonical_url":"https://www.frontierbio.com/","brief_concise":"Frontier Bio is a U.S. tissue-engineering startup pursuing two linked product lines: a patient-seeded, bioresorbable vascular graft intended for implantation and remodeling into a living blood vessel, and human tissue models such as lung and blood-brain-barrier/neural systems for preclinical testing. The central promise is plausible in concept and supported by repeated, fairly consistent company and interview claims, some partnership signals, and early preclinical/research-use positioning, but the evidence here is still weak on independent validation: most sources are company-controlled, interview-based, press-style, or investor-marketing materials, and the excerpts do not provide robust methods, sample sizes, peer-reviewed outcomes, or clinical data.","overall_score":52.89,"scientific_overall":46.3,"breakthrough_overall":62.05,"investor_overall":52.92,"last_rated_at":"2026-05-30 02:54:59.121336+00","public_url":"https://eternalsearch.net/ratings/projects/7YOQoxeA"},{"public_id":"lvaPrrIv","name":"Kind Bio","section":"bioreplacement","canonical_url":"https://kindbiotechnology.com/","brief_concise":"Kind Bio is a U.S. startup pursuing an \"integrated organ network\" platform: genetically engineered animal systems designed to grow transplantable peripheral organs while lacking higher CNS function and a normal body plan. The core promise is abundant organ supply for transplantation and, longer term, multi-organ replacement for age-related decline. The evidence is still early and mostly self-described or patent-based; there is no peer-reviewed demonstration here of functional human-ready organs, clinical efficacy, or scalable manufacturing.","overall_score":48.98,"scientific_overall":37.8,"breakthrough_overall":77.6,"investor_overall":40.87,"last_rated_at":"2026-05-27 06:44:21.11385+00","public_url":"https://eternalsearch.net/ratings/projects/lvaPrrIv"},{"public_id":"kZvLoF7o","name":"Wearable regenerative bioreactor for controlled wound healing","section":"bioreplacement","canonical_url":null,"brief_concise":"BioDome-R is an early-stage academic proof-of-concept for a small wearable regenerative bioreactor that creates a sealed local wound microenvironment and delivers short-term pro-regenerative cues in small-animal models. The strongest support in the provided evidence is not clinical efficacy but plausibility: related literature supports the relevance of mechanochemical control, wearable hydrogel patches, and flexible wound bioelectronics, while the project-specific evidence shows a concrete preclinical plan, explicit safety endpoints, and a narrow immediate goal of testing feasibility, tolerability, and biological response rather than claiming regeneration or translation.","overall_score":40.7,"scientific_overall":49.9,"breakthrough_overall":40,"investor_overall":33.08,"last_rated_at":"2026-05-29 12:14:21.160431+00","public_url":"https://eternalsearch.net/ratings/projects/kZvLoF7o"},{"public_id":"7ZqgT4Et","name":"Axxium Life","section":"brain-cognitive","canonical_url":"https://axxium.life","brief_concise":"Axxium Life presents itself as a developer of AI-powered active immunotherapy biologics aimed first at Alzheimer’s prevention and other chronic diseases, using peptide-based vaccines intended to induce patients’ own antibodies against targets such as amyloid-beta and alpha-synuclein. The strongest external support in the provided evidence is not for Axxium’s current flagship claim directly, but for related Vaxxinity/United Biomedical-linked programs: a phase 2a Alzheimer’s study, first-in-human and phase 1 alpha-synuclein studies, mouse synuclein data, and a monkey PCSK9 vaccine study. The main caution is that the most ambitious claims, including a privately controlled Phase 3 Alzheimer’s-prevention position and AI platform performance, are self-reported on company pages and not independently validated in the excerpt.","overall_score":56.91,"scientific_overall":64.95,"breakthrough_overall":60.55,"investor_overall":47.6,"last_rated_at":"2026-05-23 18:42:56.934957+00","public_url":"https://eternalsearch.net/ratings/projects/7ZqgT4Et"},{"public_id":"DfrdpOgj","name":"VITA (Hospital del Mar Research","section":"brain-cognitive","canonical_url":"https://researchmar.net","brief_concise":"VITA is a Barcelona-based, XPRIZE Healthspan semifinalist project from Hospital del Mar Research Institute, CRG, and IrsiCaixa that proposes a multimodal healthy-aging intervention centered on lamivudine, EGCG, and lifestyle change for older adults at risk of cognitive decline. The strongest public evidence is institutional: funding/selection announcements in May 2025, follow-on reporting tied to prior PENSA work, and a Jan-Jun 2026 recruitment page for a lifestyle-plus-EGCG study in adults aged 60-80 with subjective cognitive concerns. That supports real institutional activity and clinical intent, but not efficacy; public evidence still looks early, non-peer-reviewed, and partly inconsistent about whether lamivudine is already in the human study arm.","overall_score":45.1,"scientific_overall":45.95,"breakthrough_overall":40.2,"investor_overall":47.43,"last_rated_at":"2026-05-23 22:55:24.771017+00","public_url":"https://eternalsearch.net/ratings/projects/DfrdpOgj"},{"public_id":"raDebmy2","name":"Mitochondrial Bioenergetics and Ketone","section":"brain-cognitive","canonical_url":"https://mitargos.com","brief_concise":"Mitargos appears to be a US startup commercializing an R-1,3-butanediol ketone drink, MiDR1V3, and linking it to a UC San Diego-led XPRIZE Healthspan semifinalist project that plans to test whether ketone-based interventions can improve mitochondrial function and physical, cognitive, and immune outcomes in older adults; however, the supplied evidence is mostly patent/IP and review literature plus a company-linked press release, so project-specific efficacy remains unproven.","overall_score":40.65,"scientific_overall":43.8,"breakthrough_overall":34.9,"investor_overall":41.48,"last_rated_at":"2026-05-24 16:22:43.495048+00","public_url":"https://eternalsearch.net/ratings/projects/raDebmy2"},{"public_id":"ldS5WBe3","name":"LiGHT Team (Lithium as a","section":"brain-cognitive","canonical_url":null,"brief_concise":"LiGHT Team appears to center on low- or trace-dose lithium as a neuroprotective strategy for dementia, Parkinson’s disease, and related brain-aging conditions. The provided record supports substantial idea generation and patent activity, plus limited preclinical signal, but not convincing human efficacy. The main attraction is that lithium is biologically active, cheap, and already medically familiar; the main problem is that standard lithium has a narrow therapeutic window and meaningful renal, thyroid, and neurological toxicity, so the project only matters if much lower exposures still produce real CNS benefit.","overall_score":34.68,"scientific_overall":34.35,"breakthrough_overall":34.75,"investor_overall":34.93,"last_rated_at":"2026-05-24 09:07:04.840924+00","public_url":"https://eternalsearch.net/ratings/projects/ldS5WBe3"},{"public_id":"xh9RnivK","name":"Japan Longevity Consortium","section":"diagnostics-biomarkers","canonical_url":"https://juntendo.ac.jp","brief_concise":"Japan Longevity Consortium is a Japan-based academic consortium led from Juntendo University that is promoting a biomarker-guided, multi-component “Scientific Zen” healthspan program combining washoku-style diet, mild fasting, exercise, yoga/breathing, TEAS, far-infrared therapy, supplementation, and gut-focused management to improve cognition, immune function, and muscle function. The strongest signals are a senior university team, XPRIZE Healthspan Top 40 semifinalist status, and self-reported preliminary observational findings on epigenetic-age and autonomic outcomes; the main constraint is that the core efficacy claims are currently presented mostly on the consortium’s own site or institutional announcements, with limited methodological detail and no clearly linked peer-reviewed validation of the full program.","overall_score":47.07,"scientific_overall":42.15,"breakthrough_overall":41.9,"investor_overall":54.6,"last_rated_at":"2026-05-26 11:26:00.451292+00","public_url":"https://eternalsearch.net/ratings/projects/xh9RnivK"},{"public_id":"WVUkiSUC","name":"CHANGS","section":"diagnostics-biomarkers","canonical_url":"https://genomics.cn","brief_concise":"CHANGS is a newly announced 2025 Chulalongkorn University-BGI collaboration in Thailand focused on healthy aging, using omics and AI-based bioinformatics to analyze elderly health, collect volunteer samples and clinical data, and reportedly build outputs such as multi-omic aging measures and organ-aging models. The evidence supports that the project exists and has institutional backing, but not that it has yet produced validated biomarkers, intervention results, or clinical utility.","overall_score":37.94,"scientific_overall":38.45,"breakthrough_overall":36.55,"investor_overall":38.37,"last_rated_at":"2026-05-25 07:29:08.380921+00","public_url":"https://eternalsearch.net/ratings/projects/WVUkiSUC"},{"public_id":"pcxPb7Iy","name":"Team GlyNAC","section":"drug-discovery","canonical_url":"https://bcm.edu","brief_concise":"Team GlyNAC appears to be a Baylor College of Medicine-associated translational longevity project built around GlyNAC, a glycine plus N-acetylcysteine supplementation strategy intended to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects. The evidence base is suggestive but still limited: there are pilot and randomized older-adult studies reporting improvements in biomarkers and some functional measures, plus mouse studies reporting lifespan, cognition, and cardiac effects, but much of the accessible material is Baylor news coverage, small early-stage studies, or preclinical work, with human durability, safety, and hard clinical outcomes still unresolved.","overall_score":53.74,"scientific_overall":56.8,"breakthrough_overall":51.85,"investor_overall":52.24,"last_rated_at":"2026-05-25 19:51:09.174846+00","public_url":"https://eternalsearch.net/ratings/projects/pcxPb7Iy"},{"public_id":"HIpheznv","name":"Aptah Bio","section":"drug-discovery","canonical_url":"https://aptah-bio.com","brief_concise":"Aptah Bio is a U.S.-based startup developing RNA therapeutics, centered on a U1 snRNP-modulating platform it calls RNA WiCo/RNA rejuvenation, for neurodegeneration, cancer, and other age-related diseases. The strongest project-specific evidence is still preclinical: a 2024 Scientific Reports paper reports biomarker and electrophysiology improvements for APT20TTMG in Alzheimer’s iPSC-derived neurons and SAMP8 mice, while commercial databases and company posts show a broader preclinical pipeline and claimed non-dilutive funding. The core promise is unusually broad RNA-level correction across multiple proteins and pathways, but most high-claim statements come from company-controlled or promotional sources, and there is no clinical evidence yet.","overall_score":52.14,"scientific_overall":57.25,"breakthrough_overall":57,"investor_overall":44.62,"last_rated_at":"2026-05-23 07:54:08.113749+00","public_url":"https://eternalsearch.net/ratings/projects/HIpheznv"},{"public_id":"8aaiRWKG","name":"Team Twilight","section":"drug-discovery","canonical_url":"https://twlbio.com","brief_concise":"Team Twilight is a U.S. biotech startup developing active immunotherapies against pathological proteins, especially HERV-K-linked targets in ALS, with broader stated ambitions in Alzheimer’s, Parkinson’s, and chronic pain. The strongest direct evidence is the company’s own claims about its Ambifect Fc-fusion platform, leadership, and intended indications; the stronger independent evidence sits one layer back, supporting HERV-K as an ALS-related biomarker and mechanistic target class rather than validating Team Twilight’s product. The core uncertainty is that no clinical efficacy data for Team Twilight’s program are provided here.","overall_score":47.22,"scientific_overall":48.8,"breakthrough_overall":52.7,"investor_overall":42.42,"last_rated_at":"2026-05-25 02:29:13.12515+00","public_url":"https://eternalsearch.net/ratings/projects/8aaiRWKG"},{"public_id":"hvGNTtJp","name":"NYC-Vita","section":"drug-discovery","canonical_url":"https://mssm.edu","brief_concise":"NYC-Vita is a Mount Sinai-led, New York City pilot longevity trial that appears to combine home-based exercise, daily spermidine, and low-dose rapamycin or lamivudine in adults roughly 65-80, with the stated goal of improving immune function, muscle strength, cognition, and overall healthspan. The project has clear institutional backing and XPRIZE Healthspan semifinalist status, but the evidence here is mostly press, partner-content, and social posts plus secondary media coverage; there are no published trial results, and even basic questions about efficacy, mechanism, attribution, and safety remain unresolved.","overall_score":46.96,"scientific_overall":45.7,"breakthrough_overall":43.1,"investor_overall":50.47,"last_rated_at":"2026-05-24 03:29:11.331404+00","public_url":"https://eternalsearch.net/ratings/projects/hvGNTtJp"},{"public_id":"XSpzIY9f","name":"Beijing Joekai Biotechnology","section":"drug-discovery","canonical_url":"https://joekai.com","brief_concise":"Beijing Joekai Biotechnology appears to be a Beijing-based small-molecule neurodegeneration company centered on Alzheimer’s disease. The strongest direct evidence is company-assigned patenting around synthetic compounds for Alzheimer’s treatment, recent conference coverage of a Rac1 inhibitor candidate called 50561 with preclinical Alzheimer’s results, and trial listings showing a completed randomized Phase IIa study of 50561 in 68 patients with mild to moderate Alzheimer’s disease in China. The main caution is that most evidence is patent, directory, or conference metadata rather than peer-reviewed efficacy data, and no human results are provided in the supplied evidence.","overall_score":46.64,"scientific_overall":49.2,"breakthrough_overall":44.4,"investor_overall":45.8,"last_rated_at":"2026-05-26 18:12:42.190253+00","public_url":"https://eternalsearch.net/ratings/projects/XSpzIY9f"},{"public_id":"CHM47sqg","name":"RIGHT Trial","section":"drug-discovery","canonical_url":"https://pitt.edu","brief_concise":"RIGHT Trial appears to be a University of Pittsburgh-led Phase 2, 24-week, placebo-controlled trial testing subcutaneous clazakizumab, an IL-6 blocker, in older adults with frailty and mobility limitation. The central bet is that lowering inflammatory signaling can improve practical function such as walking speed, but the provided evidence is mostly participant-facing trial description and design context rather than published efficacy results, so credibility rests more on a plausible mechanism and formal trial structure than on demonstrated benefit so far.","overall_score":45.79,"scientific_overall":56,"breakthrough_overall":42.6,"investor_overall":38.84,"last_rated_at":"2026-05-24 06:13:08.362357+00","public_url":"https://eternalsearch.net/ratings/projects/CHM47sqg"},{"public_id":"VqTupYPq","name":"Nishimura Lab","section":"drug-discovery","canonical_url":"https://eaderm.com/contact/","brief_concise":"Nishimura Lab appears, on the evidence provided, to be an EADERM-linked regenerative dermatology effort built around hair follicle and epidermal stem-cell biology, especially aging- and injury-related mechanisms involving COL17A1 and stem-cell motility. The strongest project-specific signals are company pages describing stem-cell-based drug discovery and alopecia therapeutic development, plus Emi K. Nishimura-linked academic work on hair thinning, hair follicle aging, and skin regeneration. However, much of the translational evidence is still indirect: company pages are promotional, patents are claims rather than validation, and the provided paper excerpts are mostly title/metadata level rather than full results.","overall_score":45.5,"scientific_overall":47.4,"breakthrough_overall":47.85,"investor_overall":42.37,"last_rated_at":"2026-05-24 07:36:05.474482+00","public_url":"https://eternalsearch.net/ratings/projects/VqTupYPq"},{"public_id":"hzhT9LPy","name":"Klotho Longevity","section":"drug-discovery","canonical_url":"https://drgailhumble.com","brief_concise":"Klotho Longevity is a U.S. commercialization effort centered on Klotho-linked anti-aging products and procedures, led by Dr. Gail Humble and closely tied to the Klotho Skin brand. The evidence shows active branding, clinic offerings, and patent activity around Klotho production and skin-care use, but project-specific validation is thin: the strongest direct human evidence is a small 2025 pilot study of a topical Klotho serum for photoaging in 16 women, not a systemic longevity intervention.","overall_score":44.77,"scientific_overall":38.55,"breakthrough_overall":42.6,"investor_overall":51.58,"last_rated_at":"2026-05-24 17:34:46.062936+00","public_url":"https://eternalsearch.net/ratings/projects/hzhT9LPy"},{"public_id":"MQbmPRBf","name":"Cura Therapeutics and collaborators/","section":"drug-discovery","canonical_url":"https://curatherapeutics.com","brief_concise":"Cura Therapeutics appears to be a small, women-led biotech developing multifunctional fusion-protein therapeutics for metastatic cancer and age-related diseases, with recurring claims around multimodal immune activation plus anti-fibrotic and anti-senescence effects. The strongest evidence is not clinical; it is a mix of company materials, startup-program listings, platform databases with sparse detail, founder-linked patents, and older academic fusokine literature tied to Claudia Penafuerte Diaz and Jacques Galipeau. That supports a real translational program and relevant team lineage, but not validated efficacy, safety, or durable clinical progress.","overall_score":43.95,"scientific_overall":42.45,"breakthrough_overall":45.9,"investor_overall":44.05,"last_rated_at":"2026-05-24 10:31:58.137909+00","public_url":"https://eternalsearch.net/ratings/projects/MQbmPRBf"},{"public_id":"Vpwigp2m","name":"The Brigham Boston XPrize","section":"drug-discovery","canonical_url":"https://bwh.harvard.edu","brief_concise":"The Brigham-Boston XPRIZE Healthspan Team is a Mass General Brigham and Harvard-linked effort that became a Top 40 semifinalist in the seven-year, $101M XPRIZE Healthspan competition and received $250,000 in Milestone 1 funding in 2025. Led by Shalender Bhasin and JoAnn Manson, the team is running a preliminary program around an unnamed “promising new therapeutic” intended to extend healthspan and delay major age-related conditions. The evidence shows strong institutional leadership and real competition progress, but it is still an institutional announcement about pilot-stage work, not peer-reviewed efficacy evidence or a demonstrated clinical success.","overall_score":41.19,"scientific_overall":39.35,"breakthrough_overall":46.35,"investor_overall":39.57,"last_rated_at":"2026-05-24 18:53:01.949519+00","public_url":"https://eternalsearch.net/ratings/projects/Vpwigp2m"},{"public_id":"9fADr0Ld","name":"YOXLO","section":"drug-discovery","canonical_url":"https://yoxlo.com","brief_concise":"YOXLO is a Dutch longevity startup building a proprietary healthspan intervention, Youniqor, around a centenarian-inspired thesis that mitochondrial function, cellular resilience, and inflammatory control, especially NLRP3-linked immune signaling, can be modulated to preserve strength, cognition, independence, and immune function with age. The evidence supports a real company, named team, patents, a 2024 review by founder Stef Verlinden, and 2025 XPRIZE Healthspan semifinalist status, but not convincing efficacy: the intervention evidence here is mostly company claims, review-level argument, and patent positioning rather than disclosed clinical outcomes.","overall_score":37.58,"scientific_overall":31.15,"breakthrough_overall":33.4,"investor_overall":45.81,"last_rated_at":"2026-05-22 20:15:34.053644+00","public_url":"https://eternalsearch.net/ratings/projects/9fADr0Ld"},{"public_id":"J1XqOtZw","name":"TIME TRAVELER AND NUREKI","section":"drug-discovery","canonical_url":"https://ttraveler.jp","brief_concise":"TIME TRAVELER AND NUREKI presents as a University of Tokyo-linked startup pursuing healthy-aging products and therapeutics, especially plant-cell-derived exosomes and molecules said to inhibit aging-linked genes, with stated interests in cancer, frailty/sarcopenia, cachexia, supplements, and cosmetics. The strongest concrete evidence here is corporate self-description plus commercialization signals around a parsley-derived supplement (`exofull FUJI`) and broad patent-field context on plant-derived exosomes and muscle-loss indications. There is no peer-reviewed efficacy, clinical, or regulatory evidence in the provided record, so the project currently looks more like an early translational startup with ambitious claims than a validated longevity program.","overall_score":36.94,"scientific_overall":28.35,"breakthrough_overall":45.45,"investor_overall":39.13,"last_rated_at":"2026-05-25 16:59:09.742407+00","public_url":"https://eternalsearch.net/ratings/projects/J1XqOtZw"},{"public_id":"bwdyLHfm","name":"Beiwe","section":"drug-discovery","canonical_url":"https://beiwebio.com","brief_concise":"Beiwe appears to be an early therapeutic project centered on selective mTORC1 inhibition for longevity and cancer, with the core claim that it can preserve rapamycin-like benefits while avoiding mTORC2-related toxicity; however, the evidence here is mostly undated self-published website copy with no linked primary datasets, study details, patent record tied to the company, or disclosed clinical results.","overall_score":33.59,"scientific_overall":34.3,"breakthrough_overall":40.9,"investor_overall":28.39,"last_rated_at":"2026-05-23 17:28:25.272005+00","public_url":"https://eternalsearch.net/ratings/projects/bwdyLHfm"},{"public_id":"Z9dXN0EW","name":"A NEW DIMENSION","section":"drug-discovery","canonical_url":"https://aayamtx.com","brief_concise":"A NEW DIMENSION appears to be Aayam Therapeutics’ mitochondria-focused longevity effort: a drug-discovery and development project built around an undisclosed \"LADR 4\" platform and framed as delivering affordable, accessible therapeutics. The strongest external signal is selection on 2025-05-12 as an XPRIZE Healthspan Top 40 Milestone 1 awardee, but the public technical record in this evidence set is thin and mostly promotional; there is no disclosed mechanism, named candidate, preclinical dataset, or clinical outcome here.","overall_score":30.71,"scientific_overall":26.65,"breakthrough_overall":31.2,"investor_overall":33.95,"last_rated_at":"2026-05-25 05:47:56.232009+00","public_url":"https://eternalsearch.net/ratings/projects/Z9dXN0EW"},{"public_id":"f8GWjfd4","name":"Lono Jaeyak","section":"drug-discovery","canonical_url":null,"brief_concise":"Lono Jaeyak appears to be an anti-senescence composition program known only from a pending European patent application claiming formulations for rejuvenating senescent cells or delaying/preventing cellular aging. The available evidence supports IP activity and broad product positioning across possible nutraceutical, feed, and medicinal uses, but it does not show validated mechanism, preclinical efficacy, safety, or human data.","overall_score":25.86,"scientific_overall":20.9,"breakthrough_overall":30.85,"investor_overall":27.08,"last_rated_at":"2026-05-25 18:03:15.790384+00","public_url":"https://eternalsearch.net/ratings/projects/f8GWjfd4"},{"public_id":"GmGOgQch","name":"Alpha Rejuvenation","section":"drug-discovery","canonical_url":"https://hokokuken.com","brief_concise":"Alpha Rejuvenation appears to be a California-focused men’s health and wellness clinic marketing peptide therapies, testosterone replacement, erectile-dysfunction treatment, pelvic-floor therapy, NAD+, and semaglutide-based weight loss rather than a clearly documented R&D program. The strongest evidence is self-authored promotional clinic content describing services, testimonials, and operational constraints; there is little independent evidence here for efficacy, safety, or a distinctive longevity intervention, and the project’s canonical URL is undermined by a likely source-matching error involving an unrelated Japanese environmental site.","overall_score":24.47,"scientific_overall":15.2,"breakthrough_overall":15.55,"investor_overall":38.16,"last_rated_at":"2026-05-23 14:17:54.965384+00","public_url":"https://eternalsearch.net/ratings/projects/GmGOgQch"},{"public_id":"lRjeDA9e","name":"BioArmor","section":"drug-discovery","canonical_url":"https://questincubator.org","brief_concise":"BioArmor appears to be an early-stage, student-led longevity concept from the QuestX Incubator in Kuala Lumpur that reached XPRIZE Healthspan semifinalist status, but the public evidence does not disclose a validated therapeutic program. The clearest project-specific description is a June 25, 2025 Facebook post describing a speculative \"BioArmor X\" stack spanning a supplement/drink, future injection/serum, and topical gel/patch for regeneration, immunity, and age reversal, while also admitting that full age reversal, nanobots, and more extreme claims remain future-facing rather than demonstrated.","overall_score":21.61,"scientific_overall":15.7,"breakthrough_overall":22.9,"investor_overall":25.98,"last_rated_at":"2026-05-23 06:14:01.941804+00","public_url":"https://eternalsearch.net/ratings/projects/lRjeDA9e"},{"public_id":"eMgNaxQ0","name":"Rejuvenate Bio","section":"genetic-cellular-therapies","canonical_url":"https://rejuvenatebio.com","brief_concise":"Rejuvenate Bio is a San Diego startup developing one-time AAV gene therapies for age-related and chronic disease, with the clearest disclosed programs in canine mitral valve disease, desmoplakin arrhythmogenic cardiomyopathy, and partial epigenetic reprogramming. The upside case is unusually ambitious: use liver-directed or systemic gene delivery to create durable, body-wide effects from secreted factors such as FGF21 or from inducible OSK reprogramming. The evidence is still mostly preclinical, often company-reported, and the strongest claims remain limited by mouse or small pilot dog data rather than human validation.","overall_score":61.97,"scientific_overall":59,"breakthrough_overall":68,"investor_overall":60.8,"last_rated_at":"2026-05-27 08:37:38.37029+00","public_url":"https://eternalsearch.net/ratings/projects/eMgNaxQ0"},{"public_id":"PXnAt3vR","name":"Armatus Bio","section":"genetic-cellular-therapies","canonical_url":"https://armatusbio.com","brief_concise":"Armatus Bio is a U.S. late-preclinical biotech developing AAV-delivered engineered microRNA therapies for autosomal dominant neuromuscular diseases, with lead programs in CMT1A and FSHD. The strongest project-specific evidence is still preclinical: a 2026 Molecular Therapy: Nucleic Acids paper on AAV9 RNAi for CMT1A in mice and nonhuman primates, a 2026 assay-development paper for potency testing, company and partner press releases on TVR110 and ARM-201, and a pending 2025 PCT patent co-listed with Nationwide Children’s Hospital. The core bet is plausible but unproven in humans, and the main risks are delivery to the right cells at tolerable doses, over-silencing/off-target effects, AAV toxicology, manufacturing consistency, and crowded RNAi/IP competition in both DUX4 and PMP22.","overall_score":57.73,"scientific_overall":65.65,"breakthrough_overall":57.5,"investor_overall":50.94,"last_rated_at":"2026-05-26 07:31:27.485995+00","public_url":"https://eternalsearch.net/ratings/projects/PXnAt3vR"},{"public_id":"a825xYBJ","name":"Rejuvenation through Low Frequency","section":"genetic-cellular-therapies","canonical_url":"https://uthscsa.edu","brief_concise":"UT Health San Antonio’s \"Rejuvenation Through Low Frequency Ultrasound\" project is a US-based translational longevity effort testing whether low-frequency ultrasound can reverse cellular senescence without destroying cells. The strongest direct evidence is a 2025 Aging Cell paper with that core claim in its title and authors tied to UTMB and UT Health San Antonio, plus a 2025 university news report that the team became an XPRIZE Healthspan semifinalist and Milestone 1 awardee. The main caveat is that the public evidence here is still thin on quantitative outcomes, with human efficacy and safety not yet established.","overall_score":55.94,"scientific_overall":55.1,"breakthrough_overall":62.1,"investor_overall":52.83,"last_rated_at":"2026-05-24 13:30:39.625111+00","public_url":"https://eternalsearch.net/ratings/projects/a825xYBJ"},{"public_id":"Q8qlQIEs","name":"RenewalBio","section":"genetic-cellular-therapies","canonical_url":"https://renewal.bio","brief_concise":"RenewalBio is an Israel-based Weizmann spinout and startup developing \"stembroids\": human iPSC-derived developmental models intended to generate DNA-matched transplantable cells and tissues, with the clearest near-term stated target being hematopoietic stem cell applications for bone marrow failure and related transplant settings. The central promise is large-scale production of authentic, patient-matched replacement cells using embryo-like self-organization rather than conventional expansion, but the evidence here is mostly company, investor, media, and profile material rather than peer-reviewed efficacy or clinical data, so the project should be treated as ambitious and preclinical rather than validated.","overall_score":55.04,"scientific_overall":52.45,"breakthrough_overall":70.2,"investor_overall":47.84,"last_rated_at":"2026-05-23 09:14:20.384092+00","public_url":"https://eternalsearch.net/ratings/projects/Q8qlQIEs"},{"public_id":"j5TxJWMs","name":"ExoNovaX","section":"genetic-cellular-therapies","canonical_url":"https://kangstem.com","brief_concise":"ExoNovaX appears to map to Kangstem Biotech, a South Korean regenerative-medicine company developing allogeneic umbilical-cord-blood-derived mesenchymal stem cell products, organoid platforms, and related manufacturing capabilities. The strongest project-specific signal is OSCA / Furestem-OA Kit Inj. for knee osteoarthritis, described by the company as combining allogeneic MSCs with an acellular cartilage matrix; however, most direct evidence here is company-controlled website and PR material, while much of the rest is broader field-context patent literature rather than independent validation.","overall_score":48,"scientific_overall":47.4,"breakthrough_overall":49.5,"investor_overall":47.59,"last_rated_at":"2026-05-26 19:10:41.172556+00","public_url":"https://eternalsearch.net/ratings/projects/j5TxJWMs"},{"public_id":"zFsgVuRi","name":"Goda Lab","section":"genetic-cellular-therapies","canonical_url":"https://chem.s.u-tokyo.ac.jp","brief_concise":"Goda Lab’s longevity-facing program appears to center on engineered small extracellular vesicles (sEVs) for healthspan restoration, with the strongest project-specific signal coming from XPRIZE Healthspan recognition and a secondary-media description of “SHT-sEV therapy.” The core idea is plausible but still weakly validated in the provided evidence: the lab has strong technical depth in imaging, microfluidics, and cell analysis, yet the actual anti-aging therapeutic claims remain mostly self-described or media-described, with explicit unresolved risks around off-target accumulation, safety, and scalable manufacturing.","overall_score":47.74,"scientific_overall":45.25,"breakthrough_overall":53.95,"investor_overall":46.04,"last_rated_at":"2026-05-25 09:10:50.888377+00","public_url":"https://eternalsearch.net/ratings/projects/zFsgVuRi"},{"public_id":"HhOtrOvM","name":"Marcus STAMINA Team","section":"genetic-cellular-therapies","canonical_url":"https://hsl.harvard.edu","brief_concise":"Marcus STAMINA Team appears to be a U.S.-based geroscience pilot centered on whether intermittent dasatinib plus quercetin can be feasibly given to older adults with slow gait speed and mild cognitive impairment as a senolytic strategy aimed at mobility and cognition; the strongest direct evidence is a 2023 rationale-and-design paper for a 12-week, single-arm, open-label feasibility study in 12 participants, which supports serious academic sponsorship but not efficacy.","overall_score":46.01,"scientific_overall":45.7,"breakthrough_overall":48.5,"investor_overall":44.72,"last_rated_at":"2026-05-23 00:05:36.450293+00","public_url":"https://eternalsearch.net/ratings/projects/HhOtrOvM"},{"public_id":"ClR7KKQJ","name":"Precision Tuning of Endogenous TERT in Mesenchymal Stem Cells for Safe Cellular Rejuvenation","section":"genetic-cellular-therapies","canonical_url":null,"brief_concise":"This project proposes a safer alternative to blunt telomerase overexpression in mesenchymal stem cells by engineering endogenous TERT regulation as a graded \"dimmer switch,\" aiming to modestly raise telomerase output while preserving native control, stem-cell identity, and genomic stability. The core evidence is a project plan, not outcome data, so the idea is mechanistically plausible but still unproven and exposed to the usual telomerase risks: oncogenic drift, abnormal clonal expansion, telomere dysregulation, and loss of MSC function.","overall_score":42.66,"scientific_overall":52.35,"breakthrough_overall":46.6,"investor_overall":31.72,"last_rated_at":"2026-05-20 13:59:44.638194+00","public_url":"https://eternalsearch.net/ratings/projects/ClR7KKQJ"},{"public_id":"yDW1yDzP","name":"Prometheus Cell Team","section":"genetic-cellular-therapies","canonical_url":null,"brief_concise":"Prometheus Cell Team is presented in 2025 media and social sources as a Shanghai-based XPRIZE Healthspan semifinalist developing autologous “Prometheus Cells” by epigenetically reprogramming patient skin fibroblasts into stem cell-like regenerative cells intended to modulate immunity and promote tissue repair. The core idea is plausible at the field-context level because epigenetic reprogramming and iPSC technologies are well established as research paradigms, but the project-specific evidence here is weak: no primary paper, no protocol, no independent efficacy dataset, and only early, interview-level claims about small planned human testing and hints of immune/telomere improvements.","overall_score":39.37,"scientific_overall":36.05,"breakthrough_overall":46.3,"investor_overall":37.94,"last_rated_at":"2026-05-23 02:53:49.510733+00","public_url":"https://eternalsearch.net/ratings/projects/yDW1yDzP"},{"public_id":"11Z3Lbyv","name":"Mito-tags","section":"genetic-cellular-therapies","canonical_url":"https://Stanford.edu","brief_concise":"Mito-tags appears to be a Stanford/VA-linked mitochondrial delivery project built around bio-modified mitochondria for targeted administration to cells. The strongest project-specific evidence is a pending 2025 PCT patent application and an XPRIZE Healthspan milestone award signal; both support visibility and translational intent, but neither establishes efficacy, safety, or clinical readiness.","overall_score":39.35,"scientific_overall":32.3,"breakthrough_overall":60.2,"investor_overall":32.5,"last_rated_at":"2026-05-25 18:30:42.965779+00","public_url":"https://eternalsearch.net/ratings/projects/11Z3Lbyv"},{"public_id":"lh5X3ggG","name":"Exomed","section":"genetic-cellular-therapies","canonical_url":"https://exomed.com.au","brief_concise":"Exomed appears to be an exosome-centered longevity/regenerative project, but the project identity is unusually muddy: the evidence mixes a broad therapeutic-delivery platform pitch, skin/scalp regeneration marketing, a PRP-to-exosome kit, legacy Australian GI-related patents, and an older Australian company record that was cancelled in 2014. The strongest current project-like claim is that Exomed aims to use exosome-based therapies to deliver regenerative signals or targeted payloads to aging or diseased tissues, including possible neurology applications, but there is no project-specific peer-reviewed efficacy dataset in the evidence, so this remains a plausible thesis with weak validation rather than a demonstrated breakthrough.","overall_score":31.77,"scientific_overall":27.75,"breakthrough_overall":33.6,"investor_overall":34.14,"last_rated_at":"2026-05-24 00:27:22.205419+00","public_url":"https://eternalsearch.net/ratings/projects/lh5X3ggG"},{"public_id":"CoALxQdd","name":"Unlimited Bio","section":"genetic-cellular-therapies","canonical_url":"https://unlimited.bio","brief_concise":"Unlimited Bio is a promotional longevity startup centered on experimental combination gene therapies, especially VEGF and follistatin, with additional planned programs around KLOTHO, BDNF, PGC-1alpha, and hTERT. The project’s core promise is rejuvenation-oriented functional improvement across muscle, endurance, hair, cognition, and broader anti-aging claims, but the available evidence is mostly project-owned marketing copy with no dated primary results, no independent validation, and explicit disclaimers that the therapies are experimental, not FDA-approved, and delivered by third parties rather than by Unlimited Bio itself.","overall_score":31.62,"scientific_overall":26.75,"breakthrough_overall":40.8,"investor_overall":30.14,"last_rated_at":"2026-05-20 08:48:52.895902+00","public_url":"https://eternalsearch.net/ratings/projects/CoALxQdd"},{"public_id":"Gc5NzXq3","name":"Hoskinson Health and Wellness Clinic","section":"genetic-cellular-therapies","canonical_url":"https://hoskinsonhealth.com","brief_concise":"Hoskinson Health and Wellness Clinic is a Wyoming multi-specialty clinic that presents itself as a longevity- and regenerative-medicine-enabled care model, combining routine clinical services with in-house aging research, specialty care, and claimed regenerative offerings such as PRP, stem-cell-related work, and hyperbaric treatments. The strongest concrete evidence is that it built a substantial regional care footprint and recruited specialist staff, but the record is dominated by self-description, sponsored content, and founder claims, while independent reporting in January-May 2026 shows layoffs, cost pressure, and an announced closure due to lack of financial sustainability.","overall_score":27.6,"scientific_overall":29,"breakthrough_overall":18.6,"investor_overall":32.01,"last_rated_at":"2026-05-25 16:17:32.342311+00","public_url":"https://eternalsearch.net/ratings/projects/Gc5NzXq3"},{"public_id":"ztQ6EbRe","name":"The EBIMA Trial","section":"genetic-cellular-therapies","canonical_url":"https://med.miami.edu","brief_concise":"The EBIMA Trial appears to sit in a University of Miami clinical-research setting and, based on the evidence provided around mesenchymal-stem-cell and exosome therapeutics, is best understood as a patient-facing regenerative or immunomodulatory therapy project rather than a basic-science effort. The main constraint is evidentiary: the record here contains broad field-context patents and institutional background, but no direct EBIMA protocol, enrollment data, endpoints, or outcomes, so any strong claim about efficacy, indication, or maturity would be overstated.","overall_score":23.02,"scientific_overall":19.3,"breakthrough_overall":29.35,"investor_overall":22.32,"last_rated_at":"2026-05-24 01:50:51.920725+00","public_url":"https://eternalsearch.net/ratings/projects/ztQ6EbRe"},{"public_id":"eUW71swy","name":"NUS Academy for Healthy Longevity","section":"research-infrastructure","canonical_url":"https://nus.edu.sg","brief_concise":"The NUS Academy for Healthy Longevity appears to be a Singapore-based precision-geromedicine hub at NUS that combines clinical-trial infrastructure, biomarker-oriented research, education, and public-facing convening around healthy longevity. The strongest direct evidence is not intervention efficacy but organizational build-out: a clinical trial centre opened in 2025, multiple recruitment-stage or feasibility studies are described, and peer-reviewed outputs include a conceptual framework (HELO), a Singapore population survey on healthy-longevity knowledge and interest, and adjacent aging-biomarker studies. Most claims about impact, personalization, and biological-age reduction remain promotional, early-stage, or non-comparative rather than validated in robust human outcome trials.","overall_score":55.04,"scientific_overall":55.2,"breakthrough_overall":51.25,"investor_overall":57.27,"last_rated_at":"2026-05-25 20:22:58.318043+00","public_url":"https://eternalsearch.net/ratings/projects/eUW71swy"},{"public_id":"JSuQpmck","name":"Eternal Search","section":"research-infrastructure","canonical_url":"https://eternalsearch.net","brief_concise":"Eternal Search is a live longevity-focused funding and intelligence platform operated by Open Longevity (California 501(c)(3) nonprofit) that claims to reduce manual opportunity discovery by using AI-assisted curation, verification, deduplication, and relevance scoring across grants, fellowships, infrastructure support, investors, and related field signals. The strongest evidence supports it as an operating research-and-funding infrastructure product with public listings, basic traction metrics, and an API-oriented roadmap; the weakest point is that its core accuracy, coverage, and time-saving claims are self-described rather than independently validated.","overall_score":50.38,"scientific_overall":49.15,"breakthrough_overall":44.65,"investor_overall":55.04,"last_rated_at":"2026-05-20 15:20:12.845392+00","public_url":"https://eternalsearch.net/ratings/projects/JSuQpmck"},{"public_id":"5CEy22LN","name":"Singularis: reforming the communication of scientific knowledge","section":"research-infrastructure","canonical_url":"https://singularis.ac/","brief_concise":"Singularis is an early-stage scientific-knowledge platform that argues conventional papers are a bottleneck for both human readers and AI systems, and proposes converting papers into structured argumentation graphs and nanopublication-like units that link hypotheses, methods, results, conclusions, and evidence. The concrete product evidence is a beta system for PDF upload, knowledge-graph visualization, and graph-based chat, plus public claims about AI-generated paper graphs and source-linked annotations. The core idea is plausible as research infrastructure, but current evidence shows positioning and prototype functionality more clearly than validated accuracy, adoption, or field-level impact.","overall_score":48.71,"scientific_overall":45.85,"breakthrough_overall":55.45,"investor_overall":46.99,"last_rated_at":"2026-05-30 02:31:59.991465+00","public_url":"https://eternalsearch.net/ratings/projects/5CEy22LN"},{"public_id":"ZEZYGf6v","name":"Pentara Brain Stride","section":"research-infrastructure","canonical_url":"https://pentara.com","brief_concise":"Pentara Brain Stride appears to be a clinical-trial biostatistics and data-integrity offering focused on neurodegenerative disease studies, especially regulatory-facing trial design, analysis, and fraud detection. The core claim is not a new therapy but that better endpoint selection, statistical design, programming, data management, and anomaly detection can improve the truthfulness and decision value of brain-related trials. The evidence supports domain specialization and relevant personnel, but it is mostly self-description from company pages rather than independent validation, and no verified outcome metrics are provided.","overall_score":45.91,"scientific_overall":49.6,"breakthrough_overall":31.85,"investor_overall":51.46,"last_rated_at":"2026-05-27 05:49:07.786254+00","public_url":"https://eternalsearch.net/ratings/projects/ZEZYGf6v"},{"public_id":"CaIImnN2","name":"First Approval","section":"research-infrastructure","canonical_url":"firstapproval.io","brief_concise":"First Approval appears to be an early-stage scientific data publishing platform for biology and longevity-adjacent research, centered on structured dataset annotation, decentralized/encrypted storage, customizable licensing, DOI-linked publication, and incentive mechanisms for sharing. The strongest project-specific evidence points to platform positioning and a 2025 student BioData Competition run with Open Longevity, but the available record is mostly promotional and organizational copy; key public pages were not accessible in the capture, and there is no independent evidence here of meaningful adoption, data quality improvement, monetization, or research impact.","overall_score":43.2,"scientific_overall":43.35,"breakthrough_overall":42.65,"investor_overall":43.41,"last_rated_at":"2026-05-29 13:40:12.113921+00","public_url":"https://eternalsearch.net/ratings/projects/CaIImnN2"},{"public_id":"HpYscubO","name":"R42 Group","section":"research-infrastructure","canonical_url":"https://r42group.com","brief_concise":"R42 Group appears to be a U.S.-based, founder-led venture platform and family-office-derived group centered on AI, biotech, and longevity, with an adjacent education/community arm (R42 Institute). The strongest evidence supports investing activity, network-building, and public positioning around AI-plus-longevity rather than validated scientific breakthroughs or clinical outcomes. Reported signals include a $16M AI and Longevity Fund, named investments such as Fountain Therapeutics and Healx, and a 2025 XPRIZE Healthspan semifinalist mention for an R42 approach described as gene therapy plus AI-guided systems biology, but most claims are self-reported, interview-based, directory-sourced, or promotional.","overall_score":41.9,"scientific_overall":29.4,"breakthrough_overall":40.5,"investor_overall":53.72,"last_rated_at":"2026-05-25 22:13:01.651948+00","public_url":"https://eternalsearch.net/ratings/projects/HpYscubO"},{"public_id":"Y2NiQakM","name":"Omega-Point","section":"research-infrastructure","canonical_url":"https://q0.openlongevity.work/landing","brief_concise":"Omega-Point is a self-described AI experiment-design platform for longevity and biotech research that claims to turn a one-sentence scientific goal into a fully specified lab experiment via a nine-agent reasoning pipeline in about 10 minutes, producing requirement decompositions, frontier questions, competing hypotheses, and S-I-M-T protocol details. The core promise is plausible as research infrastructure, but the evidence here is almost entirely project marketing copy plus adjacent field-context preprints and patents; there is no independent validation, no benchmark against human experimental design, and no shown evidence that its outputs improve real laboratory outcomes.","overall_score":40.19,"scientific_overall":33.65,"breakthrough_overall":44,"investor_overall":43.54,"last_rated_at":"2026-05-30 00:57:12.462184+00","public_url":"https://eternalsearch.net/ratings/projects/Y2NiQakM"},{"public_id":"vbvX81Vh","name":"DTL","section":"research-infrastructure","canonical_url":"https://longevity.technology/data/","brief_concise":"DTL appears to be a UK-based longevity market-intelligence product from First Longevity / Longevity.Technology, positioned as an AI-enabled, structured data and analysis layer over longevity biotech companies, drug assets, and related signals such as trials, financing, IP, partnerships, and talent. The concrete claimed output is decision support for investors, pharma BD, and operators through searchable datasets, custom reports, and a chatbot over a live longevity corpus. The evidence supports product positioning and claimed use cases, but it is mostly self-published marketing and partnership coverage with no independent validation of data quality, model performance, user outcomes, or commercial traction.","overall_score":34.5,"scientific_overall":29.75,"breakthrough_overall":29.2,"investor_overall":41.97,"last_rated_at":"2026-05-26 11:54:34.996322+00","public_url":"https://eternalsearch.net/ratings/projects/vbvX81Vh"}],"pagination":{"total":55,"limit":50,"offset":0,"has_more":true},"access_level":"public"}